VX1 fundamentals
An in-depth look to VERTEX PHARMACEUTICAL operating, investing, and financing activities
VX1 free cash flow for Q1 24 is 1.15 B EUR. For 2023, VX1 free cash flow was 3.02 B EUR and operating cash flow was 3.2 B EUR.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM